Singapore Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their investments there as of late and either expanded existing manufacturing capabilities, or chosen the city-state as the location for a…
Singapore Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region. Asia Pacific (AP) is an immensely diverse and dynamic region with varying regulatory capabilities and capacities; consequently, AP regulators and…
APAC A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest its China neurology and allergy business for USD 680 million; and Pfizer, AstraZeneca and Novartis investing in Singaporean manufacturing. …
ASEAN A roundup of some of the most important recent pharma news from the dynamic ASEAN region, including a big new investment from Novartis in its antibody plant in Singapore, the establishment of ‘pharmaceutical ecozones’ to streamline the drug application process in the Philippines; Vietnam’s journey to attaining WHO Level Four…
Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility. Johnson & Johnson Innovation…
APAC As the COVID-19 pandemic showed, vaccination is perhaps the most important tool a country has in maintaining the health of its population. Writing in the May 2023 edition of DIA’s Global Forum magazine, Jun Feng and Alex Best of Janssen Singapore and Kristy Lim of Janssen South Korea highlight how…
APAC The latest pharma and healthcare news from Southeast Asia, including the partnership between KPJ Healthcare and Samsung; Specialised Therapeutics’ immuno-oncology therapy; Singapore biotech CytoMed Therapeutics’ IPO, the Malaysian approval of Astrazeneca’s Evusheld and CAR T-cell immunotherapy innovation in Thailand. Singapore-Sweden research reveals promising stem cell approach for restoring vision…
APAC The latest pharma and healthcare news from Southeast Asia, including the proposed healthcare programs of Thailand’s political parties for the upcoming election; Singapore’s approval of Pfizer’s 20-valent pneumococcal conjugate vaccine; the collaboration between Amgen and NSG BioLabs; Indonesian startup Etana’s new round of financing and Pharmaniaga’s financial woes. Thailand develops…
Asia-Pacific The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share purchase, China-based MGI Tech’s participation in Thailand’s genomics initiative and Boston Scientific’s expanded operations in Malaysia. GSK invests SGD…
Singapore MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants will turn out MSD’s immunotherapy for cancer and its human papillomavirus (HPV) vaccine for the Asia-Pacific region. The reason we…
Singapore Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to Singapore, where he has spent almost half of his 20-year pharma career, and take on responsibility for the vast Asia-Pacific…
Singapore The latest healthcare and pharma news from Singapore, including the partnership between Boehringer Ingelheim and A*STAR for targeted cancer therapies, Amgen’s sponsorship of biotech incubator, NSG BioLabs, and Tessa Therapeutics’ USD 126 million funding round. Boehringer Ingelheim / A*STAR partner on targeted cancer therapies (BioSpectrum Asia) Boehringer Ingelheim and…
See our Cookie Privacy Policy Here